Table 1 Characteristics of breast cancer patients included in the study
All (n = 104) | TNBC (n = 47) | HR+ BC (n = 57) | |
|---|---|---|---|
Age (years) | 54.0 (47.5-62.0) | 55.0 (43.0-62.0) | 53.0 (48.0-62.0) |
Sex | |||
Male | 1 (1.0%) | 0 (0.0%) | 1 (1.8%) |
Female | 103 (99.0%) | 47 (100.0%) | 56 (98.2%) |
Breast cancer subtype | |||
Triple negative BC (TNBC) | 47 (45.2%) | ||
HR+/HER2− BC (HR+ BC) | 57 (54.8%) | ||
Denovo metastatic disease | 25 (24%) | 11 (23.4%) | 14 (24.6%) |
Disease stage at sampling | |||
Stage IV | 104 (100.0%) | 47 (100.0%) | 57 (100.0%) |
Previous (neo)adjuvant chemotherapy | 74 (71.2%) | 35 (74.5%) | 39 (68.4%) |
Previous Lines of metastatic chemotherapy | |||
None | 56 (53.8%) | 29 (61.7%) | 27 (47.4%) |
1 line | 46 (44.2%) | 17 (36.2%) | 29 (50.9%) |
2 lines | 2 (1.9%) | 1 (2.1%) | 1 (1.8%) |
Chemotherapy naive | 17 (16.3%) | 9 (19.1%) | 8 (14.0%) |
Previous CDK4/6 inhibitor | 55 (52.9%) | 3 (6.4%) | 52 (91.2%) |
Previous adjuvant radiotherapy | 74 (71.2%) | 29 (61.7%) | 45 (78.9%) |
Previous palliative radiotherapy | 30 (28.8%) | 9 (19.1%) | 21 (36.8%) |
Initial diagnosis to sampling (months) | 63.4 (26.6-120.4) | 31.2 (12.9-86.7) | 83.2 (44.0-145.0) |
Advanced diagnosis to sampling (months) | 16.9 (2.1-30.0) | 1.9 (0.8-7.2) | 24.8 (17.5-37.5) |
Bone metastases | 72 (69.2%) | 21 (44.7%) | 51 (89.5%) |
Liver metastases | 61 (58.7%) | 17 (36.2%) | 44 (77.2%) |
Lung metastases | 34 (32.7%) | 20 (42.6%) | 14 (24.6%) |
More than 3 sites of metastases | 22 (21.2%) | 7 (14.9%) | 15 (26.3%) |
